Literature DB >> 25530004

Diagnostic profile on the IFA 40: HEp-20-10 - an immunofluorescence test for reliable antinuclear antibody screening.

Edda Rohwäder1, Michael Locke, Johanna Fraune, Kai Fechner.   

Abstract

Indirect immunofluorescence assay is the recommended gold standard to test for antinuclear antibodies (ANA), which are important biomarkers for systemic rheumatic autoimmune diseases. It is internationally accepted that indirect immunofluorescence assay ANA screening is most sensitive on human epithelial (HEp-2) cells. The cells present a multitude of antigens that display distinguishable localization patterns in interphase and mitotic cells in indirect immunofluorescence analysis. Here, we present the IFA 40: HEp-20-10 test kit (Euroimmun AG, Lübeck, Germany), which is cleared for sale on the US market by the FDA. The test has been designed for qualitative and semiquantitative screening of ANA in human sera. It uses the commonly applied 1:40 cutoff dilution and the enhanced HEp-20-10 cell line for more efficient pattern recognition and has been validated in various studies and by method comparison. The IFA 40: HEp-20-10 test fulfills the essential criteria for reliable application in autoimmune diagnostics.

Entities:  

Keywords:  HEp-20-10; antinuclear antibodies; human epithelial cell line (HEp-2); indirect immunofluorescence assay (IIFA); systemic rheumatic diseases

Mesh:

Substances:

Year:  2014        PMID: 25530004     DOI: 10.1586/14737159.2015.993612

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  2 in total

1.  Recognition and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear Autoantibodies Testing at a Community Hospital.

Authors:  John B Carter; Sara Carter; Sandra Saschenbrecker; Bruce E Goeckeritz
Journal:  Front Med (Lausanne)       Date:  2018-04-09

2.  Automated Processing and Evaluation of Anti-Nuclear Antibody Indirect Immunofluorescence Testing.

Authors:  Vincent Ricchiuti; Joseph Adams; Donna J Hardy; Alexander Katayev; James K Fleming
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.